Catalyst Pharmaceuticals Inc CPRX shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.
What Happened: Catalyst Pharmaceuticals reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 21 cents.
The company reported quarterly sales of $60.76 million which beat the analyst consensus estimate of $58.09 million by 4.59 percent. This sales figure is a 58.6% increase over sales of $38.31 million in the same period last year.
See Also: Why Esperion Therapeutics Stock Is Tanking Thursday
What Else: Catalyst Pharmaceuticals says the company achieved record full-year 2022 total net revenue of $214 million, representing a 52% increase YoY driven by consecutive quarterly FIRDAPSE net product revenue growth.
The company also reported continued growth for FIRDAPSE, achieving net product revenue of $61 million for fourth-quarter 2022, representing robust growth of a 59% increase compared to fourth-quarter 2021.
According to data from Benzinga Pro, CPRX has a 52-week high of $22.11 and a 52-week low of $6.15.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.